^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Go to data
Title:

Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

Excerpt:
Determine the recommended expansion phase dose of margetuximab in combination with pembrolizumab [ Time Frame: 9 months ] Characterize maximum tolerated dose (MTD) or maximum administered dose (MAD) (if no MTD is defined) of margetuximab when administered in combination with pembrolizumab
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA)

Published date:
10/09/2018
Excerpt:
HER2+, PD-L1-unselected, 2nd line GEA pts post T progression received Margetuximab (M)…+ Pembrolizumab (P)...Our results suggest that M+P is well tolerated and has encouraging preliminary activity in 2nd line HER2+ GEA.
DOI:
10.1093/annonc/mdy282.046
Trial ID: